Index Ventures, Novo A/S and Ventech have partially exited their investment in Funxional Therapeutics, following the company’s sale of its rights to lead anti-inflammatory drug FX 125L to German pharmaceuticals company Boehringer Ingelheim.
Asset is reportedly due to come to market in 2021, with the sale process most likely starting in H1
Redalpine has led a series-A funding round for Germany-headquartered pet healthcare startup Felmo.
GP intends to boost the company's growth and consolidate its market position in the Benelux and DACH regions
GP is deploying equity via WMS III and is investing with future managing director Holger Schmitz